To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

Summary

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

Timeline

Start

2022-06-09

Primary completion

2023-05

Completion

2023-10

Publications

• Hong H, Chen Z, Cui J, Zhang Q, Li P, Tao R, Huang H, Wang B, Li W, Wu H, Wei J, Su L, Zhang Z, Zhong M, Wang H, Wang C, Zhou H, Wang J, Dong M, Lin T. Anti-TIM-3 antibody TQB2618 in combination with penpulimab in relapsed or refractory classic Hodgkin lymphoma previously treated with PD-1/PD-L1 therapy: a multicenter, open-label, single-arm, phase Ib clinical trial. J Immunother Cancer. 2026 Apr 10;14(4):e014968. doi: 10.1136/jitc-2026-014968.

Drugs

Indications